

Peter J Greasley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3606838/publications.pdf>

Version: 2024-02-01

13
papers

572
citations

1307594

7
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

998
citing authors

#	ARTICLE	IF	CITATIONS
1	Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis. Diabetes, Obesity and Metabolism, 2018, 20, 479-487.	4.4	336
2	Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Science Translational Medicine, 2018, 10, .	12.4	91
3	Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. American Journal of Physiology - Renal Physiology, 2018, 315, F1295-F1306.	2.7	46
4	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrology Dialysis Transplantation, 2019, 34, 339-346.	0.7	28
5	Deletion of Gpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain Sensation. PLoS ONE, 2016, 11, e0167965.	2.5	24
6	Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from <scp>DAPASALT</scp> and <scp>DIAMOND</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 1578-1587.	4.4	11
7	Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to Immunosuppression. Kidney360, 2021, 2, 105-113.	2.1	10
8	Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-CHF Study Population: A Mathematical Modeling Analysis. Journal of Clinical Pharmacology, 2021, 61, 636-648.	2.0	9
9	Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 76-91.	2.5	8
10	Identification of Proteins Associated with the Early Restoration of Insulin Sensitivity After Biliopancreatic Diversion. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4157-e4168.	3.6	4
11	Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. Journal of Clinical Pharmacology, 2022, 62, 541-554.	2.0	2
12	Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data. PLoS ONE, 2022, 17, e0269970.	2.5	2
13	Development of Human Target Validation Classification that Predicts Future Clinical Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 255-261.	2.5	1